

Somatic mutations reveal hyperactive Notch signaling and racial disparities in prurigo nodularis

Ahmad Rajeh¹, Hannah L. Cornman¹, Anuj Gupta², Mindy D. Szeto¹, Anusha Kambala¹, Olusola Oladipo¹, Varsha Parthasarathy¹, Junwen Deng¹, Sarah Wheelan³, Thomas Pritchard¹, Madan M. Kwatra⁴, Yevgeniy R. Semenov^{5,6}, Alexander Gusev^{7,8}, Srinivasan Yegnasubramanian^{2,9}, Shawn G. Kwatra^{1,9}

¹Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

²The Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

³Present affiliation: National Human Genome Research Institute, National Institute of Health, Bethesda, MD, USA.

⁴Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA.

⁵Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.

⁶Department of Systems Biology, Harvard Medical School, Boston, MA, USA.

⁷Division of Genetics, Brigham & Women's Hospital, Boston, MA, USA.

⁸Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

⁹Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Corresponding author:

Shawn G. Kwatra, MD
Associate Professor of Dermatology and Oncology
Director, Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Office: Room 206, Lab: Suite 216, Koch CRBII
1550 Orleans Street, Baltimore, MD 21231, USA
Tel: 410-955-8662
Email: skwatra1@jhmi.edu

Conflict-of-interest statement

S.G.K. is an advisory board member/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Pfizer, Incyte, and Sanofi. S.Y. receives research funding to his institution from Bristol-Myers Squibb and Celgene, Janssen, and Cepheid for unrelated work and has served as a consultant for Cepheid. He owns founder's equity in Brahm Astra Therapeutics and Digital Harmonic. All other authors declare they have no competing interests.

41 **Abstract**

42 Prurigo nodularis (PN) is a chronic inflammatory skin disease that disproportionately
43 affects African Americans and is characterized by pruritic skin nodules of unknown
44 etiology. Little is known about genetic alterations in PN pathogenesis, especially relating
45 to somatic events which are often implicated in inflammatory conditions. We thus
46 performed whole-exome sequencing on 54 lesional and nonlesional skin biopsies from
47 17 PN patients and 10 atopic dermatitis (AD) patients for comparison. Somatic
48 mutational analysis revealed that PN lesional skin harbors pervasive somatic mutations
49 in fibrotic, neurotropic, and cancer-associated genes. Nonsynonymous mutations were
50 most frequent in *NOTCH1* and the Notch signaling pathway, a regulator of cellular
51 proliferation and tissue fibrosis, and *NOTCH1* mutations were absent in AD. Somatic
52 copy-number analysis, combined with expression data, showed that recurrently deleted
53 and downregulated genes in PN lesional skin are associated with axonal guidance and
54 extension. Follow-up immunofluorescence validation demonstrated increased *NOTCH1*
55 expression in PN lesional skin fibroblasts and increased Notch signaling in PN lesional
56 dermis. Finally, multi-center data revealed a significantly increased risk of *NOTCH1*-
57 associated diseases in PN patients. In characterizing the somatic landscape of PN, we
58 uncover novel insights into its pathophysiology and identify a role for dysregulated
59 Notch signaling in PN.

60

61 **Introduction**

62 Prurigo nodularis (PN) is a chronic inflammatory skin disease characterized by intensely
63 pruritic, hyperkeratotic skin nodules on the trunk and extremities (1, 2). Compared to more
64 common and better characterized chronic pruritic dermatoses like atopic dermatitis (AD) or
65 psoriasis, PN is associated with greater itch intensity (3), as well as a significant quality of life
66 impairment (4, 5). PN emerges in middle age, disproportionately affects African Americans, and
67 is associated with multiple systemic conditions (6–9). Despite this significant clinical burden, the
68 etiology of PN remains poorly understood.

69 The current understanding of PN biology centers around an interplay between
70 cutaneous inflammation, neuronal dysregulation, and altered keratinocyte differentiation and
71 fibroblast signaling (10–13). Recent transcriptomic studies show characteristic patterns of
72 immune polarization in PN patients, including both Th2/Th17-centered cutaneous immune
73 activation, and cutaneous and systemic Th22-related cytokine upregulation (10, 14). Black
74 patients have a greater genetic risk of developing PN and distinct inflammatory signatures are
75 seen in African American PN patients, suggesting the existence of multiple disease endotypes
76 (15–17). However, to which extent those patterns might be explained by genetic variation or
77 environmental exposures remains unknown. In better studied chronic pruritic dermatoses such
78 as AD and psoriasis, genomic studies have accelerated our understanding of disease pathology
79 and informed new treatments (18, 19), but similar investigations are lacking for PN.

80 The relevance of genomic studies in inflammatory skin disease includes postzygotic
81 variation. Somatic mutations throughout the body are known to drive neoplasms, but growing
82 evidence also points to clonal expansions harboring somatic mutations in non-neoplastic
83 disease and healthy-appearing tissue, including the skin (20–23). Such findings have informed
84 our understanding of both the disease and the corresponding tissue biology. For example,
85 colonic mucosa of patients with inflammatory bowel disease displays positive selection for

86 mutations in interleukin-17 pathway genes, which may confer a protective advantage to mucosal
87 epithelia (20, 24). Thus, delineating somatic events associated with PN may further our
88 understanding of not only disease pathology, but also cutaneous molecular adaptations in the
89 setting of chronic itch, fibrosis, and neuroinflammation. This is especially pressing given the
90 comorbidities in PN patients, including a higher risk of skin and internal malignancies (25, 26),
91 which remain largely unexplained.

92 In this study, we characterize the landscape of somatic events in PN lesional skin. We
93 perform whole-exome sequencing (WES) on individual-matched lesional and nonlesional skin
94 biopsies from a diverse cohort of PN patients, as well as AD patients as a reference group. We
95 explore the mutational landscape of PN at the individual nodule level, identifying somatic events
96 in lesional PN skin compared to adjacent healthy-appearing skin. We also contrast the somatic
97 profile of PN to that of AD to elucidate molecular pathways specific to PN. Our somatic analysis
98 also leads us to functional and multi-center epidemiological follow-up investigations. To our
99 knowledge, this work represents the first and largest genomic study of PN.

100

101 **Results**

102 **Whole-exome analysis**

103 An illustration of the study design is shown (Figure 1A). Briefly, we recruited 17 patients
104 from the Johns Hopkins Itch Center diagnosed with PN (Figure 1B and C) fulfilling our selection
105 criteria (see Methods). Patient demographics are summarized in Figure 1D. Two skin punch-
106 biopsies were obtained from each patient, one from a prurigo nodule (lesional) and one from
107 normal-appearing skin (nonlesional) within 10 cm of the nodule. Since high-throughput WES
108 can provide sufficient resolution for the detection of somatic events, we generated WES data
109 from 17 lesional and 17 nonlesional PN samples in this study. In the same method, we also

110 generated 20 matched WES datasets from 10 patients with AD for use as reference group
111 (Figure 1A and D).

112 From our PN cohort (34 WES datasets across 17 patients), we obtained approximately
113 1.7 billion reads (mean and range = 4.9×10^7 [4.2×10^7 to 6.1×10^7] and 5.2×10^7 [4.3×10^7 to
114 7.0×10^7] for lesional and nonlesional samples, respectively). After quality control and alignment
115 to the hg38 human reference genome, we noted an average sequencing coverage of 195 (187
116 and 202 for lesional and nonlesional, respectively). On average, more than 93% of the exome
117 was sequenced to at least 20X depth, providing a reliable signal for variant calling (27). Detailed
118 sequencing and alignment information, including results from preprocessing and variant calling
119 on our AD control cohort, is provided (Table S1). One pair of AD lesional/nonlesional samples
120 was excluded from downstream analyses because the nonlesional sample had less than 50% of
121 the exome sequenced to at least 20X depth.

122 **Somatic variation in PN lesional skin**

123 Somatic variants in PN nodules were identified by matching PN lesional to nonlesional
124 samples per patient. The landscape of somatic mutations in PN is shown in Figure 1E-H.
125 Following quality control, we identified 2387 high-confidence somatic single nucleotide
126 variations (SNVs) SNVs and small insertions/deletions (indels) in PN lesional skin affecting
127 1933 genes. Mutational analysis showed a median of 75 somatic (lesion-specific) mutations per
128 patient, including SNVs and indels. We observed a median mutational burden of approximately
129 0.52 per megabase of coding region (range of 0.26 to 9 per megabase; outlier sample was
130 further characterized in Figure S1). We noted 35% (847 of 2387), 2.0% (48 of 2387), 0.59% (14
131 of 2387), 0.58% (13 of 2387), and 0.3% (8 of 2387) missense, nonsense, splice site altering, in-
132 frame indels, and frameshift indels, respectively. After predicting the effects of variants on
133 protein function, variants were classified into significance categories “High + Moderate”,
134 indicating likely change in protein sequence, and “Low + Modifier”, indicating no known change

135 in protein sequence (Figure 1F). We found a median of 29 functional, lesion-specific somatic
136 SNVs or indels per PN patient (range of 13 to 450) (Figure 1F).

137 We observed a median somatic variant allele frequency (VAF) of 0.031 (range of 0.01 to
138 0.449) in PN lesional skin, with Caucasian PN patients displaying a higher VAF than African
139 American PN patients (0.033 compared to 0.029, $P = 0.0056$, *Wilcoxon*) (Figure 1G and H). On
140 assessment of somatic variants at the gene level, there were 46 genes with nonsynonymous
141 somatic mutations in at least two out of 17 patients with PN. We grouped recurrently-mutated
142 genes using three *a priori*-defined gene sets relevant to PN based on literature and clinical
143 judgement. There were 5 genes associated with pathologic fibrosis (*NOTCH1*, *SCN5A*, *MAP1B*,
144 *TTN*, *ITPR1*) (28), 6 genes associated with neuronal migration or projection (*MAP1B*, *RELN*,
145 *TENM1*, *CNTN2*, *NAV1*, *RGS12*) by gene ontology, and 4 cancer-associated genes (*NOTCH1*,
146 *TRRAP*, *FAT1*, *NCOA1*) according to the Cancer Gene Census (CGC) from the Catalogue of
147 Somatic Mutations in Cancer (COSMIC) (29). *NOTCH1* had the most frequent nonsynonymous
148 somatic mutations: we found 4 missense SNVs (p.Arg1962His, p.Asn70Ile, p.Glu450Lys, and
149 p.Asn325Lys) and 1 in-frame deletion (p.Val413-Asp414del) across 4 patients, 2 of whom were
150 African American. *NOTCH1* is an intracellular regulator of the Notch family with pleiotropic
151 functions in cellular proliferation and tissue fibrosis, and a known hallmark driver of cutaneous
152 squamous cell carcinoma (cSCC) (30, 31). 3 out of 5 identified *NOTCH1* mutations were within
153 the extracellular epidermal growth factor (EGF)-like domain, which is involved in ligand binding
154 and preventing constitutional activation (32). Somatic mutations in *NOTCH1* had a significant
155 co-occurrence with mutations in *NCOA1*, *MISP*, *NAV1*, *MYO1C*, *RGS12*, and *VPS13B* ($P <$
156 0.05 , pairwise *Fisher's exact test*) (Figure 2A).

157 *Genes associated with fibrosis.* In addition to *NOTCH1*, we identified somatic mutations
158 in other profibrotic genes. We noted two missense mutations in *SCN5A* (p.Gly1158Asp,
159 p.Arg1638Gln) across two PN patients. *SCN5A* encodes the alpha subunit of the Na_v1.5 sodium

160 channel, which plays a key role in the depolarization of cardiomyocytes and whose
161 channelopathy is linked to cardiac fibrosis (33). *SCN10A* from the same gene family, which
162 encodes Na_v1.8, which regulates pro-inflammatory responses in the skin and was significantly
163 upregulated in the epidermis of rosacea and psoriasis skin lesions (34).

164 We found two missense mutations in *ITPR1* (p.Ala805Val, p.Glu914Lys) affecting two
165 PN patients. *ITPR1* encodes one of the three members of the IP₃-receptor family that form
166 calcium release channels and is associated with pancreatic fibrosis (28), in addition to chronic
167 itch mediated by astrocytes (35). We also observed two recurrent missense mutations in
168 *MAP1B* (p.Val1549Gly x 2) across two patients. While *MAP1B* is thought to be primarily
169 involved in microtubule assembly and neurogenesis, it also plays a role in fibrosis, particularly in
170 the eye (28, 36).

171 In addition, we found *TTN* mutated in 3 patients including 4 missense mutations
172 (p.Ala25524Val, p.Asn8023Lys, p.Ala35193Thr, and p.Val7022Ala) and one frame-shift deletion
173 (p.Val29546AsnfsTer3). *TTN* has an established role in interstitial fibrosis and is frequently
174 mutated in numerous cancers, but it encodes the largest protein in humans and is frequently
175 mutated in reference populations (37, 38). Of note, we found a recurrent p.Ile1690Val missense
176 mutation in Epiplakin 1 (*EPPK1*) in 3 of the PN patients. While *EPPK1* was not in our pre-
177 defined gene sets, this was the only gene with 3 or more identical recurrent somatic mutations,
178 at either the DNA or amino acid level. *EPPK1* encodes a member of the plakin family which is
179 involved in the organization of cytoskeletal architecture and has been shown to accelerate
180 keratinocyte migration during wound healing (39, 40). We also found several mutations in genes
181 related to neuronal migration or projection, detailed below.

182 *Neurotropic genes.* The mutations in *MAP1B* are described above since it is found to
183 have both fibrotic as well as neurotropic functions (28, 36). *RELN*, which is involved in nerve
184 migration, projection, and synaptic plasticity was found to have two missense mutations

185 (p.Thr468Pro, p.Val167Leu) across two patients. We also found two missense mutations across
186 two patients in *TENM1* (p.Ala2661Ser, p.Gly1134Arg) and *CNTN2* (p.Ala2661Ser,
187 p.Gly1134Arg). *TENM1* encodes a protein of the teneurin subfamily which is thought to function
188 as a neuronal cellular signal transducer and is one of the most highly mutated genes in
189 melanoma (41). *CNTN2* encodes contactin 2, which is found to play an important role in
190 neuronal excitability (42). In addition, we noted two missense mutations across two patients in
191 *RGS12* (p.Gly454Asp, p.Arg403Cys) and *NAV1* (p.Pro1507Ser, p.Arg1581Cys). *RGS12* was
192 shown to be a critical modulator of serotonergic neurotransmission (43), while *NAV1* is a
193 relatively understudied gene that is involved in neuronal development and regeneration (44).

194 *Cancer-associated genes.* To identify mutations in known cancer genes, we overlapped
195 our set of 46 genes with recurrent nonsynonymous mutations and the curated CGC gene list
196 from COSMIC (29). We found recurrent mutations in known cancer genes *TRRAP*, *FAT1*, and
197 *NCOA1*. We found 3 missense mutations in *TRRAP* (p.Pro252Ser, p.Pro1364Leu,
198 p.Glu2479Lys) across two patients. *TRRAP* is involved a cell-cycle regulation and oncogenesis
199 and has been found to be recurrently mutated in melanoma (45, 46). Notably, previous work
200 showed that skin fibroblasts of individuals with *TRRAP* mutations have significant changes in
201 expression of genes associated with neuronal function and ion transport (45). *FAT1*, a regulator
202 of cell-cell adhesion and extracellular matrix architectural integrity that is a recognized driver of
203 cSCC (47), had one nonsense p.Gln2076Ter mutation and one splice site mutation across two
204 patients. We also found two missense mutations in *NCOA1* (p.Pro1102Ser, p.Ala498Thr) across
205 two PN patients.

206 We further investigated the mutation rate in known oncogenic pathways as reported by
207 The Cancer Genome Atlas (48). We found the Notch signaling pathway to be most commonly
208 mutated in our PN cohort, with variants detected in 9 out of 17 patients (52.9%), including
209 mutations in *NOTCH1*, *NOTCH4*, *CNTN6*, *FBXW7*, *JAG2*, and *SPEN*. Notch signaling is

210 followed by the RTK-RAS and Wnt pathways, which were altered in 5 (29.4%) and 4 (23.5%)
211 PN patients, respectively. A list of high-confidence somatic SNV and indel calls made in this
212 study is included in Table S2.

213 *Gene set enrichment analysis.* Gene set enrichment analysis offers a relatively unbiased
214 view into the somatic landscape at the pathway level and can highlight patterns that are too
215 subtle to identify at the gene level (49). As a proxy for the somatic selection, we first conducted
216 an enrichment analysis of high-VAF (>0.3) nonsynonymous somatic mutations. Different
217 patterns by race were observed (Figure 2). Notably, high-VAF mutations in African American PN
218 patients were associated with epithelial-to-mesenchymal transition (*NOTCH4* and *TASOR*;
219 FDR-adjusted $P < 0.05$).

220 We then performed enrichment analysis of all genes that were found to have recurrent
221 nonsynonymous somatic mutations in PN lesions. We included pathways from 3 term
222 databases: Gene Ontology (GO) Biological Process, GO Cellular Component, and NCI-Nature
223 Pathways. After correction for multiple hypothesis testing, the most significantly mutated
224 networks were related to Notch-mediated signaling, neuronal migration, and polymeric
225 cytoskeletal fiber (Figure2, B-D).

226 Since we identified *NOTCH1* as the most frequently mutated gene in PN lesional skin,
227 and loss-of-function mutations in *NOTCH1* have been established to occur commonly in cSCC
228 (50), we compared our PN somatic calls to a publicly available cSCC variant dataset from a
229 recent metaanalysis by Chang et al. (47). We included 83 cSCC samples for this analysis, with a
230 median tumor mutational burden and VAF of 21.4 per megabase and 0.258, respectively. Not
231 surprisingly, cSCC samples had a significantly higher mutational burden and VAF than our PN
232 samples ($P < 0.001$, *Wilcoxon*) (Figure 3A and B). *NOTCH1* was mutated in 55.4% of cSCC
233 samples, second only to *TTN*. Overall, there were 6 genes that mutated in 25% or more of the
234 cSCC samples and also in two or more samples of our PN cohort: *NOTCH1*, *FAT1*, *TTN*, *FLG*,

235 and *RELN* (Figure 3C-E). Out of those genes, *NOTCH1* and *FAT1*, are the ones previously
236 identified as likely cSCC drivers (47) (Figure 3C-E). In addition, *TASOR2*, a gene found to be
237 differentially regulated in several cancers but whose function remains understudied (51), was
238 the only gene not mutated in any of the cSCC samples while having somatic mutations in two of
239 our PN patients.

240 **Somatic copy number variation in PN**

241 In addition to somatic SNVs and indels, somatic copy-number variation (CNV) may
242 contribute to the phenotype of PN phenotype by altering gene dosage. Copy number analysis of
243 exome data identified a median of 66 somatic CNVs per PN patient (range of 48 to 344),
244 including characteristic recurrent deletions in chromosome 1p13 (6/17; 35%), 4p (5/17; 29%),
245 4q13.2 (4/17; 24%), 5q (3/17; 18%), 7q21 (3/17; 18%), 11q14 (5/17; 29%), 12 (7/17; 41%), and
246 19q13.42 (4/17; 24%). Since the method we used gives a greater weight to high amplitude
247 events that are less likely to occur by chance, we also identified significant gains in
248 chromosome 7p22 and chromosome 17q25.3 in one sample ($P < 0.05$; see Methods). We noted
249 distinct patterns of recurrent somatic CNV in PN by race: Caucasian patients more commonly
250 had deletions in chromosome 1p13.3 (4/5; 80%) and duplications in chromosome 15 (3/5; 60%),
251 whereas African American patients more commonly had deletions involving chromosome 4p
252 (5/12; 42%), 4q13.2 (4/12; 33%), 7q21 (3/12; 25%), 11q14 (5/12; 42%), and 12 (5/12; 42%)
253 (Figure 4A-C). Overall, recurrent somatic deletions had an overlap with 3173 gene loci and
254 somatic duplications overlapped with 5 gene loci: *FOXK2*, *WDR45B*, *EIF3B*, *RSPH10B2*, and
255 *CCZ1B*.

256 Previous studies show that CNV affects gene expression and biological processes (52,
257 53). To investigate the functional impact of somatic CNV in PN, we overlapped genes affected
258 by recurrent somatic CNV calls in our PN cohort with genes found to be differentially expressed
259 in PN lesional skin using RNA-seq data (10). We identified 264 genes that were significantly

260 downregulated (FDR-adjusted $P < 0.05$; log fold-change < 0) as well as recurrently deleted in
261 PN lesional skin. Enrichment analysis of those 264 genes showed that the deleteriously affected
262 pathways were most significantly related to neural crest cell development, negative regulation of
263 chemotaxis, and negative regulation of axonal extension (Figure 4E). Manual review of the
264 enrichment results revealed that it was primarily driven by a recurrent 7q21 deletion affecting
265 *SEMA3C*, *SEMA3E*, *SEMA3A*, and *SEMA3D* (Figure 4D). There were two gene loci that
266 overlapped recurrently duplicated segments and were significantly upregulated in PN lesional
267 skin: *FOXK2* and *EIF3B*.

268 Since not all of the RNA-seq samples we used overlapped with the WES samples, and
269 to demonstrate that the enrichment in neurotropic pathways is driven by somatic deletions, we
270 repeated the enrichment analysis using expression data only as a negative comparator—there
271 was no significant enrichment in those neuronal pathways without CNV information (Figure S2).

272 We then performed CNV signature analysis to investigate the common etiology, if any, of
273 such wide-scale somatic events. We identified 3 CNV signatures in our samples based on loss-
274 of-heterozygosity status, total copy number state, and segment length. One CNV signature was
275 highly similar to known signature CN12 from the COSMIC curated database (0.837 cosine
276 similarity), which is believed to be a focal loss-of-heterozygosity signature indicating
277 chromosomal instability in association with a enome doubling event (54). African American and
278 Caucasian patients displayed similar exposure to CN12 ($P = 0.58$, *Fisher's exact test*) (Figure
279 4F-G).

280 **Somatic mutational landscape of PN compared to AD**

281 *Distinct somatic mutational landscape in PN.* Somatic mutational analysis of AD lesional
282 skin revealed a median of 75 lesion-specific mutations per patient (range of 37 to 1161), with
283 the highest frequency of recurrent nonsynonymous somatic mutations in *TTN* (4/9; 44%),
284 *DNHD1* (3/9; 33%), *USP20* (3/9; 33%), and *ANKRD36* (3/9; 33%) (Figure 5 A). Of note, none of

285 the AD samples had somatic mutations in *NOTCH1* (Figure 5D). Somatic mutations in AD
286 lesional skin had a median mutational burden of 0.66 per megabase (range of 0.28 to 92.7) and
287 median VAF of 0.04 (range of 0.010 to 0.405), which were significantly higher than those of PN
288 ($P < 0.001$, *Wilcoxon*) (Figure 5B and E).

289 To investigate the somatic mutational landscape more characteristic of PN compared to
290 AD, we started with the set of 46 genes that had nonsynonymous mutations in at least two PN
291 patients and filtered those genes that had any nonsynonymous mutations in our AD cohort. This
292 analysis yielded 21 genes for PN. We performed enrichment analysis on the resulting gene list.
293 The most significant pathways were related to the Notch-mediated HES/HEY network, E2F
294 transcription factor network, microtubule cytoskeleton, neuron migration, and others (Figure 5F
295 and G).

296 We found a nonsense mutation (p.Trp1374Ter) and two missense mutations
297 (p.Glu1017Gly, p.Ser1067Leu) across two AD patients in *DUOX2*. Notably, the same nonsense
298 mutation in *DUOX2* appeared in one PN sample and this is the only recurrent nonsense
299 mutation we observed across both conditions. *DUOX2* is primarily responsible for the release of
300 hydrogen peroxide through NADPH oxidase and variant protein products have been associated
301 with elevated plasma IL17C levels (55, 56).

302 *Mutational signatures.* Analysis of the mutational processes in PN and AD lesional skin
303 identified the presence of 4 single-nucleotide substitution (SBS) and 2 double-nucleotide
304 substitution signatures (DBS). SBS signatures were most similar to SBS7b (UV exposure;
305 similarity: 0.966), SBS6 (DNA mismatch repair; similarity: 0.806), and SBS5 (unknown etiology,
306 similarity: 0.781), from the COSMIC database (57) (Figure 5A). SBS5 has unknown etiology but
307 it is found to have increased burden in many cancer types and is clock-like in that its exposure
308 correlates with the age of the individual (57). We also detected a de-novo SBS signature in AD
309 and PN characterized by frequent A[T>]G and G[C>T]C substitutions. SBS signatures had

310 similar distribution across PN and AD groups. DBS signatures only correlated with DBS1 (UV
311 exposure; similarity: 0.999), characterized by transcriptional bias with more CC>TT
312 substitutions. We also identified a de-novo DBS signature characterized by frequent TG>CA
313 substitutions. For each detected mutational signature, a multiple linear regression model was
314 built to test if age, sex, PN diagnosis (compared to AD diagnosis), and itch intensity significantly
315 predicted the corresponding signature's exposure. The regression model of DBS1 was
316 statistically significant (goodness-of-fit adjusted $R^2 = 0.66$, $P = 0.004$). DBS1 was significantly
317 associated with PN diagnosis ($\beta = 0.779$, $P < 0.001$) and itch intensity ($\beta = 0.187$, $P = 0.003$).

318 *Immunofluorescence analysis.* Our somatic analyses identified *NOTCH1* as the most
319 frequently mutated gene in PN lesional skin. As functional validation, we performed
320 immunofluorescent (IF) staining of four lesional and four matching nonlesional PN samples
321 confirmed to have mutations in *NOTCH1*. Representative skin section images are shown in
322 Figure 7A. Intensive staining for the notch intracellular domain (NICD), an indicator of active
323 Notch signaling, was observed in both lesional and nonlesional skin of PN patients. However,
324 NICD showed significantly higher expression in lesional dermis compared to nonlesional dermis
325 from the same PN patients ($t(3) = 5.92$, $P = 0.010$, *paired Student's t-test*). There was no
326 significant difference in NICD expression between lesional and nonlesional PN epidermis ($t(3) =$
327 -0.226 , $P = 0.836$) (Figure 7B and C). PN lesional skin had significantly higher co-localization of
328 Notch1 with vimentin, a relatively specific marker for fibroblasts, compared to nonlesional skin of
329 the same patients ($t(3) = 4.77$, $P = 0.018$) (Fig 7 D & E). While *NOTCH1* also co-localized with
330 KRT10, a keratinocyte marker, there was no significant difference in co-localization between
331 lesional and nonlesional PN skin ($t(3) = -2.09$, $P = 0.128$) (Figure S2).

332 *Multi-center analysis.* To test and demonstrate the clinical relevance of our findings for
333 PN patients, we first identified the top 10 non-congenital, nonredundant diseases with the
334 highest evidence for *NOTCH1* involvement, as determined by the gene-disease association

335 (GDA) score from DisGeNET (58). Highest GDAs included aortic valve calcification (0.65),
336 precursor T-cell lymphoblastic leukemia/lymphoma (0.6), and head and neck SCC (0.6). We
337 then leveraged a multi-center cohort through the TriNetX Research Network. 42,397 PN patients
338 without a history of any neoplasms were identified. Controls were identified through 1:1
339 propensity-score matching based on age, sex, race, ethnicity, smoking status, and history of
340 hypertension (Figure 8A; Table S3). Compared to matched controls, PN patients had a higher
341 relative risk (RR, [95% confidence interval]) of precursor T-cell lymphoblastic
342 leukemia/lymphoma (5.33, [2.88 to 9.88]), head and neck SCC (4.19, [3.22, 5.45]), cervical
343 cancer (3.00, [1.85 to 4.80]), breast cancer (2.91, [2.50, 3.40]), bladder cancer (2.83, [1.924,
344 4.158]), connective tissue disease (2.48, [2.15, 2.87]), aortic valve calcification (1.96, [1.78,
345 2.18]), and aortic aneurysm (1.93, [1.680, 2.219]) (Figure 8B). There was no significant
346 increased risk for adenoid cystic carcinoma or glioblastoma in PN patients.

347 **Discussion**

348 This is the first study to our knowledge to comprehensively investigate somatic
349 mutational events in PN, and we identified recurrent nonsynonymous somatic mutations in PN
350 lesional skin related to the Notch pathway. Increased Notch signaling was observed in PN
351 lesional dermis, along with increased *NOTCH1* expression in fibroblasts from PN lesional skin.
352 PN patients were also found to be at an increased risk of several *NOTCH1*-associated
353 conditions compared to matched controls. Additional findings related to PN biology include
354 downregulated and somatically deleted genes in PN lesional skin associated with neuronal
355 pathways, driven by a 7q21 deletion only seen in African American PN patients. Finally, PN
356 patients had significantly more UV-associated mutational signatures compared to AD patients,
357 after controlling for age and race.

358 Our findings highlight a role for Notch signaling in PN pathology. The Notch intracellular
359 pathway is highly conserved and plays key roles in specifying cell fates during normal tissue

360 development and homeostasis (59). Abnormal Notch signaling has been implicated in various
361 human diseases and neoplasms (60). Our study identifies *NOTCH1* as the gene with most
362 frequent nonsynonymous somatic mutations in PN. Enrichment analysis revealed that
363 recurrently mutated genes in PN were significantly related to the Notch-mediated HES/HEY
364 network, even after filtering genes mutated in AD controls. *NOTCH1* mutations have been
365 strongly associated with multiple malignancies, including cSCC—a recent meta-analysis of 83
366 cSCCs using multiple cancer gene discovery methods found *NOTCH1* as the top driver gene of
367 cSCC (47). In the present study, *NOTCH1* was the most recurrently mutated gene in PN, and
368 *NOTCH1* mutations significantly co-occurred with *NCOA1* mutations of the same oncogenic
369 pathway, suggesting a proliferative attribute to PN lesional skin. Our comparison between PN
370 and cSCC somatic data also identified *FAT1* as a recurrently mutated gene in our PN samples,
371 another high-confidence driver of cSCC. PN patients are more likely than the general population
372 to have coexisting health conditions, including malignancies (1, 61). In particular, we previously
373 found PN patients at increased risk of developing SCC (25). The present study also found an
374 association between PN and several malignancies using a multi-center cohort, and further found
375 new associations between PN and *NOTCH1*-associated conditions.

376 In addition to its role in cellular proliferation, Notch signaling also has established roles in
377 tissue fibrosis in several diseases, including renal, hepatic, pulmonary, and myocardial fibrosis
378 (62–65). The profibrotic effect of Notch1 is likely a function of fibroblast proliferation,
379 myofibroblast differentiation, and immune dysregulation through TGF- β signaling (30, 66, 67).
380 Activation of Notch signaling was observed in the lesional skin of patients with systemic
381 sclerosis, and stimulation of healthy dermal fibroblasts with a Notch1 ligand resulted in a
382 phenotype similar to that of systemic sclerosis with increased release of collagen and
383 differentiation of resting fibroblasts into myofibroblasts (68). Interestingly, these findings are

384 aligned with single-cell RNA sequencing studies indicating increased myofibroblasts in PN
385 lesional skin (14).

386 Given its immunomodulating properties, hyperactive Notch signaling further contributes
387 to fibrosis by inducing an M2 to M1 (proinflammatory) macrophage polarization, leading to
388 myofibroblasts proliferation and recruitment of fibrocytes (69). The transition between M2 and
389 M1 macrophages is also induced by IL-31 (70), which helps connect Notch dysregulation,
390 inflammatory cytokine release, and itch propagation to tissue fibrosis (71, 72). Further,
391 transcriptomic analysis of liver cancer hepatocytes shows a correlation in *NOTCH1* expression
392 and *POSTN*, which encodes periostin (73). Periostin, an extracellular matrix protein released by
393 skin fibroblasts, is found in the dermis of patients with PN at levels that correlate with itch
394 intensity (74). Recent single-cell studies in PN showed significantly increased periostin in
395 lesional skin and supports a fibroblast-neuronal axis in PN regulated by periostin (14).
396 Hyperactivation of a compromised Notch1 receptor may be one possible mechanism by which
397 somatic mutations in *NOTCH1* lead to the clinical cutaneous fibrosis observed in PN lesional
398 skin. IF analysis demonstrated both significantly increased Notch signaling in lesional PN
399 dermis and increased expression of *NOTCH1* in lesional PN skin fibroblasts. Due to its
400 profibrotic and proinflammatory roles, and its relatively high mutation rate and activation in PN
401 lesional skin, our study identifies *NOTCH1* as a driver in PN biology and Notch signaling as a
402 putative target for therapeutics (60).

403 This study also finds significant somatic mutations in neuronal pathways. Notch1 is
404 known to inhibit neurite outgrowth in neurons, and inhibition of hyperactive Notch signaling can
405 reverse neurogenesis and neurite outgrowth defects (75, 76). We also observed recurrent
406 nonsynonymous mutations in genes related to neuron projection including *MAP1B*, *TENM1*, and
407 *CNTN2*, which were not mutated in AD. Those genes were also found to be significantly
408 downregulated in PN lesional skin compared to nonlesional skin (10), suggesting the mutations

409 lead to altered neuronal structure in PN lesional skin. Further, analysis of somatic CNV in PN
410 reveals that recurrently deleted segments affect genes which are most significantly related to
411 neural crest development and negative regulation of axon extension.

412 Previous functional studies on lesional and nonlesional PN skin biopsies show altered
413 intraepidermal and dermal nerve fiber density (77). Our mutational profiles suggest primary
414 neuronal gene dysregulation in PN lesional skin. This is supported by association studies
415 showing a correlation between a PN diagnosis and other systemic neuropathies (78).

416 Following our somatic CNV analysis, enrichment in axonal growth and guidance was
417 largely due to a recurrent 7q21 deletion that overlaps with *SEMA3A* and related genes of the
418 Semaphorin–plexin signaling pathway. This deletion was only observed in African American
419 patients. This is notable in light of the disproportionate burden of PN in skin of color patients,
420 with African Americans having a 3.4 to 4.4 times increased odds of developing PN compared to
421 Whites (26, 61). In addition to CNV differences, we also observed unique high-*VAF* mutations
422 affecting epithelial-to-mesenchymal transition African American PN patients, suggesting a
423 distinct somatic evolutionary landscape in those patients. This is remarkable given that African
424 Americans with PN often present much differently than Caucasian patients with more fibrotic
425 lesions (Figure 1B and C). Previous transcriptomic studies suggest unique patterns of immune
426 polarization in African American patients with PN (15). Somatic CNV analysis in this study adds
427 further molecular foundation for the high rate of PN in African Americans and suggests a novel
428 disease endotype may exist in these patients.

429 We observed other mutations that suggest a branch of common etiology between PN
430 and AD. The only recurrent nonsense mutation in PN and AD was in *DUOX2*, which is involved
431 in the release of hydrogen peroxide through NADPH oxidase (55). *DUOX2* is highly sensitive to
432 mutation, and altered protein products have been associated with elevated plasma IL17C levels,
433 which is characteristic of the inflammatory profiles of AD and psoriasis (55). Transcriptional and

434 functional studies show elevated Th17 signatures in PN patients as well, both in the skin and
435 systemically (10, 79). However, the difference in PN is that its immunophenotype is more likely
436 an imbalance between Th17 and Th22, with elevated levels of IL-22 (10). Interestingly, Notch
437 signaling is shown to promote IL-22 secretion and the skewing of naïve CD4⁺T cells toward
438 Th22 cells (80). Further, Notch1 inhibition was shown to effectively alleviate the severity of
439 psoriasis-like skin inflammation by regulating Th17 differentiation and function (81). Hyperactive
440 Notch1 signaling can also destabilize regulatory T cells (82, 83), leaving way for unrestrained
441 Th2-driven inflammation and itch (84). The Notch pathway was found highly mutated and
442 hyperactive in PN lesional in this study, providing support and a genomic context to the
443 Th17/Th22-skewed immunologic signature of PN. This is an area where precision therapeutics
444 will make an impact, as each PN patient's treatment can be informed by their immunologic or
445 genomic signature.

446 To investigate the etiology of somatic mutational processes we observed, we performed
447 mutational signature analysis in PN and compared it to that of AD. The relative frequency of
448 DBS1, a highly specific signature for UV exposure with frequent tandem CC>TT mutations, was
449 significantly associated with PN. This was after controlling for age, race, and itch intensity.
450 DBS1 significantly correlated with itch intensity in both conditions. *NOTCH1* is one of the most
451 highly mutated genes in sun-exposed versus non-sun-exposed normal human skin samples
452 (85), and chronic UV-A exposure was shown to expand dermal fibroblasts harboring *NOTCH1*
453 amplifications (86). Subacute skin-barrier damage maybe an early-event in PN patients that
454 increases susceptibility to UV-induced DNA damage, paving the way for accumulated somatic
455 mutations and exacerbating dysregulation in the skin microenvironment. Interestingly, we did
456 not find DBS1 associated with age. Previous work shows a similar pattern in skin fibroblasts
457 where UV-associated DNA damage did not correlate with age, suggesting a proliferative origin
458 (87).

459 We recognize some limitations in our study. First, we only sequenced samples from 17
460 PN cases and 10 AD controls, although PN is a relatively rare condition (61). Thus, we may
461 have missed somatic events relevant to PN in a subset of patients. In addition, CNV analysis
462 using WES data is limited in scope and cannot delineate all complex somatic structural
463 variations. Nonetheless, our study represents the first and largest genomic sequencing effort for
464 a rare and understudied disease. Our characterization of the somatic landscape in PN reveals
465 novel insights into its pathology. Aberrant Notch signaling is identified as a likely driver in PN
466 development, likely through profibrotic and immune deregulatory functions, with potential
467 systemic involvement. We also provide support for the neuronal dysregulation pathophysiology
468 of PN through identifying recurrent loss-of-function mutations in *MAP1B*, *TENM1*, and *CNTN2*,
469 as well as recurrent copy number deletions supported by gene expression data. Finally, our
470 mutational signature analysis revealed a strong association between DBS1 and PN, suggesting
471 a potential role for UV-exposure in PN development or maintenance. Our findings represent
472 much needed progress to profile PN on the molecular level.

473 **Methods**

474 *Sample collection.* Patients diagnosed with moderate-to-severe PN, with more than 20 nodules
475 and a Worst-Itch Numeric Rating Scale (WINRS) score (88) of more than 7 out of 10 were
476 recruited from the Johns Hopkins Itch Center. For AD controls, patients diagnosed with
477 moderate-to-severe AD with a validated Investigator Global Assessment (vIGA) score (89) of
478 greater than or equal to 3 and a WINRS score of more than 7 out of 10 were recruited from the
479 Johns Hopkins Itch Center. 6-mm punch biopsies from lesional PN or AD skin and healthy,
480 nonlesional skin within 10 cm of the nodule were collected. Half of each biopsy was formalin-
481 fixed, paraffin-embedded (FFPE) and the other half was stored in RNALater solution (Ambion).
482 All patients signed a consent form approved by the local Institutional Review Board.

483 *Whole-exome analysis.* Library preparation was performed with the SureSelectXT reagent kit
484 before hybridization. SureSelect XT Human All Exon V5 library was used for hybridization.
485 NovaSeq6000 S4 was used for sequencing 150 bp paired-end reads. Illumina's CASAVA
486 (v1.8.4) was used to convert BCL files to FASTQ files. Initial quality control was performed using
487 FastQC (v0.11.8). Trimgalore (v0.6.7) (90) was used to trim adapters, low-quality base calls,
488 and short reads using default parameters. Following the “Best Practices” workflow suggested by
489 the Broad Institute, BWA-mem (v0.7.17) (91) was used for alignment against the hg38 reference
490 genome, Piccard-tools (v2.9.0) were used to mark duplicate reads, GATK (v3.8.0)
491 IndelRealigner (92) was used to clean indel artifacts, and GATK BaseRecalibrator was used to
492 recalibrate base quality scores and improve downstream variant calling. Samtools (v1.10) (93)
493 and GATK were used to determine coverage at different levels of partitioning and aggregation.
494 One AD sample was excluded due to low coverage (see Results). GATK MuTect2 was used to
495 call somatic. To focus on somatic events relevant to the development of a prurigo nodule, and to
496 further reduce the likelihood of germline calls, MuTect2 paired mode was used with lesional and
497 nonlesional samples as the “tumor” and normal samples, respectively. The default parameters
498 were used. Common germline variants and artifacts were filtered using a panel of normal
499 exomes from the ExAC database; variants present in 2 or more samples within the panel of
500 normals were removed. Somatic variants were then filtered using the following criteria: minimum
501 phred quality of 20, minimum read depth of 20, and minimum variant allele frequency of 0.01.
502 The functional effects of passed somatic SNVs and indels were then predicted using SnpEff
503 (v5.0) (94). The R package Maftools (v2.21.05) (95) was used to summarize and visualize
504 variant calls.

505 After variant calling, we considered excluding a hypermutated AD sample with 34,228
506 detected somatic variants after filtration. The rest of the AD samples had a median of 83.5
507 variants (range of 48 to 578). While this high number of variants might represent significant

508 underlying germline variation or technical artifacts, it may also reflect true hypermutation related
509 to AD. Since this study did not focus on investigating AD pathology, and the AD variants were
510 rather primarily used to curate a gene list that is more likely to be specific to PN somatic
511 mutagenesis, the hypermutated AD sample was not excluded.

512 *Gene set enrichment analysis.* Enrichr (96) was used to perform gene set enrichment analysis
513 using the following term databases: GO Biological Process, GO Cellular Component, and NCI
514 Nature Pathways. Significant GO terms and pathways were calculated using an alpha level of
515 0.05 after applying the Benjamini–Hochberg correction and output was visualized in R.

516 *Copy number analysis.* Somatic CNV was inferred using CNVkit (v0.9.4) (97), using baited
517 genomic regions for the whole-exome target capture kit S04380110 (i.e. SureSelect Human All
518 Exon V5). Nonlesional samples were combined into a pooled reference for CNV calling, as
519 opposed to an individual-matched analysis, which is the recommendation of the CNVkit authors
520 for reduced CNV noise. Significantly recurrent CNV segments were identified using CNVRanger
521 (98), which implements the statistical approach described by Beroukhim et al. to highlight
522 regions that are aberrant more often than would be expected by chance, with greater weight
523 assigned to high-amplitude events (homozygous deletions or high-level copy-number gains)
524 (99).

525 *RNA-seq data.* In order to corroborate and contextualize the functional impact of somatic CNV
526 calls, we utilized in-house gene expression data from lesional and non-lesional PN samples.
527 Differential expression pipeline is described previously (100). Briefly, normalization and
528 differential expression of RNA-seq data was carried out using the DESeq2 (101) R package,
529 with adjustment for multiple hypothesis testing using Benjamini-Hochberg. Genes with adjusted-
530 P less than 0.05 and \log_2 fold-change change < 0 or > 0 were considered down- and
531 upregulated, respectively. A relatively permissive absolute fold-change cutoff was used to allow
532 enrichment to be driven by somatic CNVs.

533 *Mutational signature analysis.* Mutational signatures for the landscape of single nucleotide
534 substitution (SBS), double nucleotide substitution (DBS), and CNV across exomes were
535 extracted based on the non-negative matrix factorization method previously described and
536 implemented in the Sigminer R package (v2.1.7) (102, 103). CNV signatures were classified as
537 recently described by Steele et al.; in brief, to capture biologically relevant copy number
538 features, a CNV signature encodes the copy number profile of a sample by summing the counts
539 of segments into a 48-dimensional vector based on total copy number, heterozygosity status,
540 and segment size (54). The optimal number of mutational signatures to extract was determined
541 by inspecting the cophenetic correlation coefficient, an indicator of the robustness of consensus
542 matrix clustering, and choosing the minimal number of signatures after which the coefficient
543 starts sharply decreasing (104). Signatures were then compared with the curated set of
544 COSMIC signatures v3.3 (57) using cosine similarity. Signatures with less than 0.7 similarity to
545 any known signatures in COSMIC were considered de-novo.

546 *Mutational burden.* We calculated mutational burden as the number of nonsynonymous
547 mutations occurring per megabase of coding regions.

548 *Shannon Diversity Index for somatic mutations.* Variant-allele frequency (VAF; v) was inferred
549 as the number of reads supporting the variant allele, SNV or indel, divided by the total reads
550 supporting the reference allele and the reads supporting the variant allele. Assuming we
551 sequenced n sites, the Shannon Diversity Index, H , for a sample was then calculated as:

552
$$H = - \sum_{i=1}^n v_i \ln v_i$$

553 *Immunofluorescence analysis.* We selected four PN patients whom we found to have *NOTCH1*
554 mutations. Lesional and nonlesional FFPE skin samples of 5- μ m thickness were deparaffinized
555 and subjected to heat-induced antigen retrieval using Trilogy buffer (Trilogy® 920P x1, Sigma-
556 Aldrich) and treated with DAKO protein blocking reagent (X0909, DAKO, Carpinteria, CA, USA).
557 The slides were then incubated with primary antibodies for Notch1 (ab52627, Abcam, 1:150)

558 and human NICD (AF3647, R&D Systems; dilution, 1:20) at 4°C overnight, followed by reaction
559 with conjugated secondary antibodies, DAPI intranuclear stain (62248, Thermofisher Scientific)
560 and mounted with ProLong Glass Antifade Mountant (P36980, Thermofisher Scientific). For
561 quantification, photomicrographs were obtained with Leica SP8 confocal microscope (Leica
562 Microsystems, Deerfield, IL, USA) at 20x objective and x63 objective oil immersion using
563 instrument settings. Background normalized fluorescence intensity of the antibodies in the
564 epidermis and dermis was measured in arbitrary units (AU) using Image J software (NIH,
565 Bethesda, MD, USA).

566 *Gene-disease associations.* We used DisGeNET (v7.0) (58) to identify diseases associated with
567 *NOTCH1*. At the time of the study, DisGeNET had 1,134,942 gene-disease associations
568 (GDAs) between 21,671 genes and 30,170 diseases. Their methodology ranks diseases based
569 on a GDA score which gives a higher weight to associations reported by several expert-curated
570 databases and with a large number of supporting publications (58). We excluded congenital
571 conditions (e.g., bicuspid aortic valve) and redundant terms (e.g., malignant neoplasm and
572 breast neoplasm: only breast neoplasm was included). The 10 remaining diseases with the
573 highest GDA were then selected as *a priori* primary outcomes in our PN cohort study.

574 *Cohort study.* The TriNetX Research Network is an international, federated clinical database
575 which contains approximately 107 million patient records at the time of this study. We first
576 identified patients with a diagnosis of PN without any previous history of neoplasms before PN
577 diagnosis. We utilized the International Classification of Diseases 10th Revision Clinical
578 Modification (ICD-10-CM) code L28.1, which is given mostly by dermatologists and has been
579 validated (105). Controls were identified through 1:1 propensity-score matching based on age,
580 sex, race, ethnicity, smoking status, and history of hypertension. Primary outcomes were
581 determined through corresponding ICD-10-CM codes and association was determined through

582 cumulative relative risk estimated using the TriNetX analytics web platform. All TriNetX analyses
583 were completed on 02/10/2023.

584 *Statistics.* Statistical tests and visualizations were performed using R (version 4.2.0).
585 Adjustment for false-discovery rate (FDR) due to multiple hypothesis testing was conducted
586 using the Benjamini–Hochberg method. An alpha level of 0.05 was used to denote significance.

587 *Study approval.* This study was approved by the Johns Hopkins Institutional Review Board
588 (IRB00231694).

589 **Acknowledgements**

590 S.G.K. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases
591 of the National Institutes of Health under Award Number K23AR077073 and a grant from the
592 Skin of Color Society. The content is solely the responsibility of the authors and does not
593 necessarily represent the official views of the National Institutes of Health. We thank the Sidney
594 Kimmel Comprehensive Cancer Center Experimental and Computational Genomics Core,
595 receiving support through NCI grant P30CA006973, for assistance with the WES next
596 generation sequencing studies and analysis. We also thank the PN and AD patients who
597 donated tissue samples for this study.

598 **Author contributions**

599 SGK, SY, AG, YRS, MMK, TP, and AR designed the study. VP, JD, HC, AK, and SVR collected
600 the data. AR, AG, MDS, and SW analyzed the data. HC, AK, and OO performed staining. AR
601 and SGK wrote the first version of the manuscript. All authors reviewed and edited the
602 manuscript.

603

604 **References**

605 1. Kwatra SG. Breaking the Itch–Scratch Cycle in Prurigo Nodularis. *N Engl J Med.* 2020;382(8):757–758.

- 606 2. Kwatra SG. Prurigo Nodularis. *JAMA Dermatol.* 2022;158(3):336.
- 607 3. Steinke S, et al. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses:
608 Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity
609 and Burden of Pruritus (PruNet) cross-sectional trial. *J Am Acad Dermatol.* 2018;79(3):457-463.e5.
- 610 4. Whang KA, et al. Health-related quality of life and economic burden of prurigo nodularis. *J Am Acad*
611 *Dermatol.* 2022;86(3):573–580.
- 612 5. Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis. *Clin Exp Dermatol.*
613 2021;46(7):1277–1284.
- 614 6. Whang KA, et al. Racial and Gender Differences in the Presentation of Pruritus. *Medicines.*
615 2019;6(4):98.
- 616 7. McColl M, et al. Pruritus in Black Skin: Unique Molecular Characteristics and Clinical Features. *J Natl*
617 *Med Assoc.* 2021;113(1):30–38.
- 618 8. Sutaria N, et al. Racial disparities in mortality among patients with prurigo nodularis: A multi-center
619 cohort study. *J Am Acad Dermatol.* 2022;86(2):487–490.
- 620 9. Wongvibulsin S, et al. A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare
621 Utilization in the United States. *J Invest Dermatol.* 2021;141(10):2530-2533.e1.
- 622 10. Belzberg M, et al. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune
623 Polarization. *J Invest Dermatol.* 2021;141(9):2208-2218.e14.

- 624 11. Sutaria N, et al. Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene
625 Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. *J Invest Dermatol.*
626 2022;142(9):2537–2540.
- 627 12. Parthasarathy V, et al. Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory
628 biomarkers in prurigo nodularis: A cluster analysis. *Front Med.* 2022;9.
629 <https://www.frontiersin.org/articles/10.3389/fmed.2022.1011142>. Accessed February 20, 2023.
- 630 13. Deng J, et al. Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis
631 compared to atopic dermatitis. *Front Med.* 2022;9:1022889.
- 632 14. Patel JR, et al. Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo
633 nodularis [preprint]. 2023;2023.01.29.526050.
- 634 15. Sutaria N, et al. Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a
635 Distinct Systemic Inflammatory Signature in African Americans. *J Invest Dermatol.* 2022;142(5):1300-
636 1308.e3.
- 637 16. Parthasarathy V, et al. The blood proteomic signature of prurigo nodularis (PN) reveals distinct
638 inflammatory and neuropathic endotypes: a cluster analysis. *J Am Acad Dermatol.* 2023;0(0).
639 <https://doi.org/10.1016/j.jaad.2023.01.042>.
- 640 17. Vasavda C, et al. A polygenic risk score for predicting racial and genetic susceptibility to prurigo
641 nodularis. *J Invest Dermatol.* 2023.
- 642 18. Brown SJ. Molecular mechanisms in atopic eczema: insights gained from genetic studies. *J Pathol.*
643 2017;241(2):140–145.

- 644 19. Zhou X, et al. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin
645 Treatment Difference. *Int J Mol Sci*. 2017;18(2):295.
- 646 20. Olafsson S, Anderson CA. Somatic mutations provide important and unique insights into the biology
647 of complex diseases. *Trends Genet*. 2021;37(10):872–881.
- 648 21. Martincorena I, et al. High burden and pervasive positive selection of somatic mutations in normal
649 human skin. *Science*. 2015;348(6237):880–886.
- 650 22. Klonowska K, et al. Ultrasensitive profiling of UV-induced mutations identifies thousands of
651 subclinical facial tumors in tuberous sclerosis complex. *J Clin Invest*. 2022;132(10).
652 <https://doi.org/10.1172/JCI155858>.
- 653 23. Olafsson S, et al. Effects of psoriasis and psoralen exposure on the somatic mutation landscape of
654 the skin [preprint]. 2022;2022.07.04.22277086.
- 655 24. Nanki K, et al. Somatic inflammatory gene mutations in human ulcerative colitis epithelium. *Nature*.
656 2020;577(7789):254–259.
- 657 25. Larson VA, et al. Association between prurigo nodularis and malignancy in middle-aged adults. *J Am*
658 *Acad Dermatol*. 2019;81(5):1198–1201.
- 659 26. Boozalis E, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. *J Am Acad*
660 *Dermatol*. 2018;79(4):714-719.e3.
- 661 27. Koboldt DC. Best practices for variant calling in clinical sequencing. *Genome Med*. 2020;12(1):91.

- 662 28. Gu C, et al. Identification of Common Genes and Pathways in Eight Fibrosis Diseases. *Front Genet.*
663 2021;11. <https://www.frontiersin.org/articles/10.3389/fgene.2020.627396>. Accessed September 10,
664 2022.
- 665 29. Sondka Z, et al. The COSMIC Cancer Gene Census: describing genetic dysfunction across all human
666 cancers. *Nat Rev Cancer.* 2018;18(11):696–705.
- 667 30. Condorelli AG, et al. Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the
668 multifaceted Notch signalling pathway. *J Biomed Sci.* 2021;28(1):36.
- 669 31. Fukusumi T, Califano JA. The NOTCH Pathway in Head and Neck Squamous Cell Carcinoma. *J Dent*
670 *Res.* 2018;97(6):645–653.
- 671 32. Sakamoto K, et al. Distinct roles of EGF repeats for the Notch signaling system. *Exp Cell Res.*
672 2005;302(2):281–291.
- 673 33. Remme CA. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological,
674 molecular and genetic aspects. *J Physiol.* 2013;591(Pt 17):4099–4116.
- 675 34. Zhang Y, et al. Nav1.8 in keratinocytes contributes to ROS-mediated inflammation in inflammatory
676 skin diseases. *Redox Biol.* 2022;55:102427.
- 677 35. Shiratori-Hayashi M, et al. Astrocytic STAT3 activation and chronic itch require IP3R1/TRPC-
678 dependent Ca²⁺ signals in mice. *J Allergy Clin Immunol.* 2021;147(4):1341–1353.
- 679 36. Ma X-X, et al. PiT2 regulates neuronal outgrowth through interaction with microtubule-associated
680 protein 1B. *Sci Rep.* 2017;7(1):17850.

- 681 37. Verdonschot JAJ, et al. Titin cardiomyopathy leads to altered mitochondrial energetics, increased
682 fibrosis and long-term life-threatening arrhythmias. *Eur Heart J*. 2018;39(10):864–873.
- 683 38. Akinrinade O, Koskenvuo JW, Alastalo T-P. Prevalence of Titin Truncating Variants in General
684 Population. *PLoS ONE*. 2015;10(12):e0145284.
- 685 39. Wesley T, et al. The attributes of plakins in cancer and disease: perspectives on ovarian cancer
686 progression, chemoresistance and recurrence. *Cell Commun Signal*. 2021;19(1):55.
- 687 40. Szabo S, Wögenstein KL, Fuchs P. Functional and Genetic Analysis of Epiplakin in Epithelial Cells.
688 *Methods Enzymol*. 2016;569:261–285.
- 689 41. Peppino G, et al. Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets
690 for Therapy. *Int J Mol Sci*. 2021;22(5):2321.
- 691 42. Stogmann E, et al. Autosomal recessive cortical myoclonic tremor and epilepsy: association with a
692 mutation in the potassium channel associated gene CNTN2. *Brain J Neurol*. 2013;136(Pt 4):1155–1160.
- 693 43. White AN, et al. Genetic deletion of Rgs12 in mice affects serotonin transporter expression and
694 function in vivo and ex vivo. *J Psychopharmacol Oxf Engl*. 2020;34(12):1393–1407.
- 695 44. Klimke W, et al. The National Center for Biotechnology Information’s Protein Clusters Database.
696 *Nucleic Acids Res*. 2009;37(suppl_1):D216–D223.
- 697 45. Cogné B, et al. Missense Variants in the Histone Acetyltransferase Complex Component Gene TRRAP
698 Cause Autism and Syndromic Intellectual Disability. *Am J Hum Genet*. 2019;104(3):530–541.
- 699 46. Wei X, et al. Exome sequencing identifies GRIN2A as frequently mutated in melanoma. *Nat Genet*.
700 2011;43(5):442–446.

- 701 47. Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. *NPJ*
702 *Genomic Med.* 2021;6(1):61.
- 703 48. Sanchez-Vega F, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. *Cell.*
704 2018;173(2):321-337.e10.
- 705 49. Reimand J, et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA,
706 Cytoscape and EnrichmentMap. *Nat Protoc.* 2019;14(2):482–517.
- 707 50. Hedberg ML, et al. Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma. *Int J Mol Sci.*
708 2022;23(7):3478.
- 709 51. Su AI, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. *Proc Natl Acad*
710 *Sci U S A.* 2004;101(16):6062–6067.
- 711 52. Stranger BE, et al. Relative Impact of Nucleotide and Copy Number Variation on Gene Expression
712 Phenotypes. *Science.* 2007;315(5813):848–853.
- 713 53. Zhou C, et al. Integrated Analysis of Copy Number Variations and Gene Expression Profiling in
714 Hepatocellular carcinoma. *Sci Rep.* 2017;7(1):10570.
- 715 54. Steele CD, et al. Signatures of copy number alterations in human cancer. *Nature.*
716 2022;606(7916):984–991.
- 717 55. Grasberger H, et al. DUOX2 variants associate with preclinical disturbances in microbiota-immune
718 homeostasis and increased inflammatory bowel disease risk. *J Clin Invest.* 2021;131(9).
719 <https://doi.org/10.1172/JCI141676>.

- 720 56. Guttman-Yassky E, Krueger JG. IL-17C: A Unique Epithelial Cytokine with Potential for
721 Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. *J Invest Dermatol.* 2018;138(7):1467–
722 1469.
- 723 57. Alexandrov LB, et al. The repertoire of mutational signatures in human cancer. *Nature.*
724 2020;578(7793):94–101.
- 725 58. Piñero J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic Acids*
726 *Res.* 2020;48(D1):D845–D855.
- 727 59. Shen W, Huang J, Wang Y. Biological Significance of NOTCH Signaling Strength. *Front Cell Dev Biol.*
728 2021;9. <https://www.frontiersin.org/articles/10.3389/fcell.2021.652273>. Accessed September 25, 2022.
- 729 60. Allen F, Maillard I. Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders.
730 *Front Cell Dev Biol.* 2021;9. <https://www.frontiersin.org/articles/10.3389/fcell.2021.649205>. Accessed
731 September 8, 2022.
- 732 61. Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: Epidemiology and clinical features. *J Am Acad*
733 *Dermatol.* 2020;83(6):1559–1565.
- 734 62. Yang YM, et al. Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation
735 and liver fibrosis. *Sci Transl Med.* 2019;11(496):eaat9284.
- 736 63. Yu C, et al. Histone demethylase JMJD3 protects against renal fibrosis by suppressing TGFβ and
737 Notch signaling and preserving PTEN expression. *Theranostics.* 2021;11(6):2706–2721.
- 738 64. Zhou Y, et al. Astragalus injection attenuates bleomycin-induced pulmonary fibrosis via down-
739 regulating Jagged1/Notch1 in lungs. *J Pharm Pharmacol.* 2016;68(3):389–396.

- 740 65. Lu L, et al. FSTL1-USP10-Notch1 Signaling Axis Protects Against Cardiac Dysfunction Through
741 Inhibition of Myocardial Fibrosis in Diabetic Mice. *Front Cell Dev Biol.* 2021;9:757068.
- 742 66. Ma S, et al. Survivin promotes rheumatoid arthritis fibroblast-like synoviocyte cell proliferation, and
743 the expression of angiogenesis-related proteins by activating the NOTCH pathway. *Int J Rheum Dis.*
744 2021;24(7):922–929.
- 745 67. Wang Y-C, et al. Notch1 promotes the pericyte-myofibroblast transition in idiopathic pulmonary
746 fibrosis through the PDGFR/ROCK1 signal pathway. *Exp Mol Med.* 2019;51(3):1–11.
- 747 68. Dees C, et al. Notch signalling regulates fibroblast activation and collagen release in systemic
748 sclerosis. *Ann Rheum Dis.* 2011;70(7):1304–1310.
- 749 69. Keewan E, Naser SA. Notch-1 Signaling Modulates Macrophage Polarization and Immune Defense
750 against Mycobacterium avium paratuberculosis Infection in Inflammatory Diseases. *Microorganisms.*
751 2020;8(7):1006.
- 752 70. Kan T, et al. IL-31 induces antitumor immunity in breast carcinoma. *J Immunother Cancer.*
753 2020;8(2):e001010.
- 754 71. Ständer S, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. *N Engl J Med.*
755 2020;382(8):706–716.
- 756 72. Deng J, et al. Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to
757 Severe Prurigo Nodularis Treated With Nemolizumab. *JAMA Dermatol.* 2023;e232609.
- 758 73. Kongkaviton P, et al. Regulation of periostin expression by Notch signaling in hepatocytes and liver
759 cancer cell lines. *Biochem Biophys Res Commun.* 2018;506(3):739–745.

- 760 74. Hashimoto T, et al. Dermal Periostin: A New Player in Itch of Prurigo Nodularis. *Acta Derm Venereol.*
761 2021;101(1):adv00375.
- 762 75. Berezovska O, et al. Notch1 inhibits neurite outgrowth in postmitotic primary neurons.
763 *Neuroscience.* 1999;93(2):433–439.
- 764 76. Winanto, et al. Organoid cultures of MELAS neural cells reveal hyperactive Notch signaling that
765 impacts neurodevelopment. *Cell Death Dis.* 2020;11(3):1–8.
- 766 77. Schuhknecht B, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo
767 nodularis skin as a potential sign of subclinical cutaneous neuropathy. *Br J Dermatol.* 2011;165(1):85–91.
- 768 78. Hughes J-DM, et al. Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy:
769 Suggesting a Role for Neural Dysregulation in Pathogenesis. *Medicines.* 2020;7(1):4.
- 770 79. Wong L-S, et al. IL-17A Induces Endothelin-1 Expression through p38 Pathway in Prurigo Nodularis. *J*
771 *Invest Dermatol.* 2020;140(3):702-706.e2.
- 772 80. Zeng C, et al. The NOTCH-HES-1 axis is involved in promoting Th22 cell differentiation. *Cell Mol Biol*
773 *Lett.* 2021;26(1):7.
- 774 81. Ma L, et al. Effect of γ -secretase inhibitor on Th17 cell differentiation and function of mouse
775 psoriasis-like skin inflammation. *J Transl Med.* 2018;16(1):59.
- 776 82. Benamar M, et al. The Notch1/CD22 signaling axis disrupts Treg function in SARS-CoV-2–associated
777 multisystem inflammatory syndrome in children. *J Clin Invest.* 2023;133(1).
778 <https://doi.org/10.1172/JCI163235>.

- 779 83. Rivas MN, Arditi M. Notch1 signaling impairs regulatory T cells during multisystem inflammatory
780 syndrome in children. *J Clin Invest*. 2023;133(1). <https://doi.org/10.1172/JCI166016>.
- 781 84. Singer BD, D'Alessio FR. Regulatory T cell Itch reins in Th2 inflammation. *Cell Mol Immunol*.
782 2014;11(2):126–128.
- 783 85. Wei L, et al. Ultradeep sequencing differentiates patterns of skin clonal mutations associated with
784 sun-exposure status and skin cancer burden. *Sci Adv*. 2021;7(1):eabd7703.
- 785 86. Katarkar A, et al. NOTCH1 gene amplification promotes expansion of Cancer Associated Fibroblast
786 populations in human skin. *Nat Commun*. 2020;11(1):5126.
- 787 87. Abyzov A, et al. One thousand somatic SNVs per skin fibroblast cell set baseline of mosaic mutational
788 load with patterns that suggest proliferative origin. *Genome Res*. 2017;27(4):512–523.
- 789 88. Ständer S, et al. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation. *J*
790 *Eur Acad Dermatol Venereol JEADV*. 2022;36(4):573–581.
- 791 89. Simpson E, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The
792 development and reliability testing of a novel clinical outcome measurement instrument for the severity
793 of atopic dermatitis. *J Am Acad Dermatol*. 2020;83(3):839–846.
- 794 90. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads.
795 *EMBnet.journal*. 2011;17(1):10–12.
- 796 91. Fast and accurate short read alignment with Burrows–Wheeler transform | Bioinformatics | Oxford
797 Academic [Internet]. <https://academic.oup.com/bioinformatics/article/25/14/1754/225615>. Accessed
798 September 18, 2022.

- 799 92. McKenna A, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-
800 generation DNA sequencing data. *Genome Res.* 2010;20(9):1297–1303.
- 801 93. Li H, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* 2009;25(16):2078–
802 2079.
- 803 94. Cingolani P, et al. A program for annotating and predicting the effects of single nucleotide
804 polymorphisms, SnpEff: SNPs in the genome of *Drosophila melanogaster* strain w¹¹¹⁸₁; iso-2; iso-3. *Fly*
805 (*Austin*). 2012;6(2):80–92.
- 806 95. Mayakonda A, et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer.
807 *Genome Res.* 2018;28(11):1747–1756.
- 808 96. Kuleshov MV, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.
809 *Nucleic Acids Res.* 2016;44(Web Server issue):W90–W97.
- 810 97. Talevich E, et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted
811 DNA Sequencing. *PLOS Comput Biol.* 2016;12(4):e1004873.
- 812 98. da Silva V, et al. CNVRanger: association analysis of CNVs with gene expression and quantitative
813 phenotypes. *Bioinformatics.* 2020;36(3):972–973.
- 814 99. Beroukhi R, et al. Assessing the significance of chromosomal aberrations in cancer: Methodology
815 and application to glioma. *Proc Natl Acad Sci.* 2007;104(50):20007–20012.
- 816 100. Belzberg M, et al. Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22
817 Immune Polarization. *J Invest Dermatol.* 2021;141(9):2208-2218.e14.

- 818 101. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
819 with DESeq2. *Genome Biol.* 2014;15(12):550.
- 820 102. Alexandrov LB, et al. Deciphering signatures of mutational processes operative in human cancer.
821 *Cell Rep.* 2013;3(1):246–259.
- 822 103. Wang S, et al. Sigflow: an automated and comprehensive pipeline for cancer genome mutational
823 signature analysis. *Bioinformatics.* 2021;37(11):1590–1592.
- 824 104. Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. *BMC*
825 *Bioinformatics.* 2010;11(1):367.
- 826 105. Roh YS, et al. Validation of International Classification of Diseases Tenth Revision code for prurigo
827 nodularis. *J Am Acad Dermatol.* 2022;87(2):482–484.

828

829

830 **Figure 1. Somatic mutational landscape of PN.** (A) Schematic of the study design including sample
831 collection and analysis. (B, C) Example skin images of two patients with prurigo nodularis (PN) enrolled in
832 this study. (B) Dorsal left arm of an African American patient with scattered prurigo nodules. (C) Right arm
833 of a Caucasian patient with scattered prurigo nodules. (D) Demographic information of PN and atopic
834 dermatitis (AD) patients. (E) Waterfall plot displaying somatic mutations in 15 of the most frequently
835 mutated genes in PN lesional skin compared to nonlesional skin. Ties were broken by known gene
836 function. Columns represent the 17 PN patients. Numbers shown on the right indicate the frequency of
837 gene mutation. Total nonsynonymous somatic SNPs and indels per sample are displayed on top. One
838 sample was hypermutated with 450 mutations. Bottom plot shows the frequency of different classes of
839 SNVs. Variants annotated as Multi Hit are those genes which mutated more than once in the same
840 sample. (F) Total number of somatic mutations per sample, broken down by predicted impact on protein
841 product based on snpEff, with functional (High or Moderate) impact in yellow and nonfunctional (Low or
842 Modifier) in blue. (G) Boxplot showing the variant allele frequency (VAF) of nonsynonymous somatic
843 mutations across race. (H) **, $P < 0.01$.

844

845

846

847

848 **Figure 2. Distinct somatic selection in lesional skin of African American patients with PN. (A)**
849 Nonsynonymous somatic mutations are ordered by their genomic locations on the x-axis and the
850 corresponding VAF is shown on the y-axis. Variants with 0.3 or higher VAF are labelled with their gene
851 name. (B and C) Bar graph showing the pathway enrichment results of high-VAF (>0.3) nonsynonymous
852 mutations in African American and Caucasian PN patients, respectively.

853

854

855 **Figure 3. Co-occurrence and enrichment of recurrent somatic mutations in PN lesional skin. (A)**
856 Somatic mutational correlation matrix of all 46 genes with recurrent nonsynonymous somatic mutations in
857 PN lesional skin. Significant pairs were identified with Fisher's exact test. (B-D) Gene ontology (GO) term
858 and pathway enrichment results of recurrently-mutated genes across three pathway databases. Terms
859 with FDR-corrected $P < 0.05$ are colored in yellow.

860

861 **Figure 4. Somatic mutations in PN and cSCC.** (A) Rank order plot showing the somatic mutational
862 burden (number of nonsynonymous mutations occurring per megabase of coding regions) across 17 PN
863 patients and 83 cutaneous squamous cell carcinoma (cSCC) patients. Red dashed line indicates the
864 median mutational burden. Inset is a boxplot comparison of somatic mutational burden between the two
865 cohorts. (B) Boxplot showing VAF of all nonsynonymous somatic variants in cSCC and PN patients. (C)
866 Venn diagram depicting the overlap between known cSCC driver genes, genes that were found mutated
867 in 25% or more of the 83 cSCC samples (cSCC recurrent), and genes that were found mutated in 2 or
868 more of our 17 PN samples (PN lesional recurrent). (D, E) Somatic mutations falling within the *NOTCH1*
869 and *FAT1*, respectively. y-axis indicates the number of PN (top) or cSCC (bottom) patients the carrying
870 the somatic mutation. Colored rectangles indicate known functional domains of the protein product. EGF,
871 epidermal growth factor; LamG, laminin G.

872

873

874 **Figure 5. Landscape of somatic CNV in PN.** (A) Normalized copy number per sample per chromosome
875 for African American and Caucasian patients. (B) Circular plot illustrating the proportion of samples with
876 deletions (red) and duplications (blue) per genomic region for African American patients (outer ideogram)

877 and Caucasian patients (inner ideogram). (C) Examples of recurrent somatic CNV events only observed
878 in African American patients or Caucasian patients on chromosomes 12 and 15, respectively. (D) RNA-
879 seq data was used to determine differentially down- and up-regulated genes in PN lesional skin.
880 Transcript log₂ fold-change is shown on the y-axis with respect to genomic location on chromosome 7 on
881 the x-axis. Overlaid red box shows the location of the recurrent 7q21 somatic deletion. (E) GO term
882 enrichment results of 264 genes that overlapped recurrent deletions while also being differentially
883 downregulated in PN lesional skin. Terms with FDR-corrected $P < 0.05$ are colored in yellow. (F)
884 Decomposition plot showing the relative contributions of CNV signature components to the three somatic
885 CNV signatures detected (HomDel: homozygous deletion, LOH: loss-of-heterozygosity). (G) Distribution
886 of CNV signatures in African American and Caucasian PN patients.

887

888 **Figure 6. Somatic mutational differences between PN and AD.** (A) Ten genes with the most frequent
889 nonsynonymous somatic mutations in our AD cohort. (B) All nonsynonymous somatic mutations in AD
890 and PN are ordered by their genomic locations on the x-axis and the corresponding VAF is shown on the
891 y-axis. Variants with 0.3 or higher VAF are labelled with their gene name. (C) Histograms showing the
892 frequency of nonsynonymous somatic variants on the x-axis at the corresponding VAF on the y-axis, in
893 AD and PN. P -value indicates the significant difference in means (*Wilcoxon*). (D) Mutational diversity per
894 sample using a normalized Shannon Diversity Index based on the VAF of somatic SNVs and indels in PN
895 and AD patients. One hypermutated AD sample was not excluded (see Methods). (E) The top mutated
896 genes in our PN cohort are illustrated, with the corresponding relative frequency and percentage of
897 alteration in AD and PN samples. (F) Rank order plot showing the somatic mutational burden per
898 megabase across 17 PN patients, 9 AD patients, and all 33 cancers in The Cancer Genome Atlas cohort.
899 Red lines indicate the median mutational burden. A dictionary for cancer symbols is included in Table S3
900 (G, H) GO term enrichment results of 21 genes with nonsynonymous somatic mutations in at least two PN
901 samples and no AD samples across two pathway databases. Terms with FDR-corrected $P < 0.05$ are
902 colored in yellow.

903

904 **Figure 7. Somatic mutational signatures in PN and AD.** (A) Decomposition plot of the 4 somatic SBS
905 signatures detected showing the relative proportion of each transition and transversion subtype. (B)
906 Distribution of SBS signatures in PN and AD samples. The inset figure shows the relative exposures of
907 mutational signature types. Not shown, but included in all analyses, is a hypermutated AD sample with
908 >20,000 instances of SBS5. (C) Boxplot showing the distribution of SBS signatures in PN compared to
909 AD. (D) Decomposition plot of the two somatic DBS signatures detected showing the relative proportion
910 of each base-pair mutation subtype. (E) Distribution of DBS signatures in PN and AD samples. The inset
911 figure shows the relative exposures of DBS signature types. Samples not shown did not display any
912 known DBS signatures (E) Partial regression plots of DBS1 on each of age, race, itch intensity, and
913 condition (PN versus AD), after controlling for the remaining covariates. Overall model adjusted $R^2 = 0.66$.


914

915 **Figure 8. Notch signaling is activated in lesional skin of PN patients.** (A) IF staining of NICD in
916 lesional and nonlesional skin sections of a PN patient with a *NOTCH1* somatic mutation. Representative
917 skin sections are shown at 189-fold magnification of the dermis. NICD (green), DAPI (blue). (B & C)
918 Paired boxplot showing the difference in relative expression of NICD between lesional and nonlesional
919 PN dermis (B) and epidermis (C). (D) IF staining of Notch1 and vimentin in lesional and nonlesional skin
920 sections of a PN patient. Notch1 (red), vimentin (green), DAPI (blue). Representative skin sections are
921 shown at 189-fold magnification of the dermis. (E) Paired boxplot showing the difference in relative co-
922 localization of Notch1 and vimentin between PN lesional and nonlesional skin.


923

924 **Figure 9. Higher risk of *NOTCH1*-associated diseases in PN patients.** (A) A multi-center cohort of PN
925 patients and propensity-score matched controls was obtained using the TriNetX Research Network. The
926 top 10 acquired, non-redundant diseases associated with *NOTCH1* were determined based on available
927 literature support using the DisGeNET database (B) Cumulative relative risk of *NOTCH1*-associated
928 diseases in PN patients compared to matched controls. LL/L, lymphoblastic leukemia/lymphoma; H&N
929 SCC, head and neck squamous cell carcinoma; ***, $P < 0.0001$; ns, no significant difference in risk.


A Data collection



Analysis




B




C




E



F




G










D






Characteristic	PN Group (N = 17)	AD Group (N = 10)
Age - yr ± SE	51.2 ± 3.47	44.8 ± 5.7
Age >60 - no. (%)	4 (23.5)	3 (30)
Male sex - no. (%)	5 (29.4)	2 (20)
Black race - no. (%)	12 (71)	6 (60)
White race - no. (%)	5 (29)	4 (40)


H











A**B****C**

















A**B****C****D****E**

A**B**